Phosphodiesterase type 5 inhibitor use among pregnant and reproductive-age women in the United States.

Wei LiuTalia J MenzinCorinne M WoodsNicole R HaugJie LiJustin A MathewChristine P NguyenGrace P ChaiDavid G MoenyMayura Shinde

Published in: Pharmacoepidemiology and drug safety (2020)

We found a low prevalence of PDE5 inhibitor use in pregnant and reproductive-age women. Given the very low prevalence of use and the inconsistency of neonatal mortality data across STRIDER centers, the risk to public health is low at present.

Keyphrases

public health
risk factors
polycystic ovary syndrome
pregnant women
pregnancy outcomes
type diabetes
cardiovascular events
cardiovascular disease
metabolic syndrome
big data
adipose tissue
cervical cancer screening
insulin resistance
data analysis